In addition, we identified brain-enriched, HLA-A*02:01-binding and MTX-241F-exclusive immunopeptides that represent treatment-induced changes and may serve as biomarkers of therapeutic response or potential targets for CAR-T cell-based approaches.<h4>Discussion</h4>MTX-241F changes the glioma immunopeptidome, unveiling H2B1K, brain-enriched, and treatment-induced immunopeptides as immunologically visible targets. Here, HLA-A is linked to central nervous system cancer.